This article discusses the Medicare drug benefit legislation and its requirements for privacy and security
FDA to Evaluate Lenacapavir for Prevention of HIV
A PDUFA target action date for the PrEP therapy has been set for June 19, 2025.
Pharmacists as the Authority on Ultra-High-Cost Drugs
Erin Fox, PharmD, MHA, BCPS, FASHP, joined Drug Topics to discuss ultra-high-cost drugs and the American Society of Health-System Pharmacists 2025 Pharmacy Forecast.
Maximum (Un)Fair Price
How pharmacies will pay for the Medicare Drug Price Negotiation Program
Team-Based Care Crucial in Addressing Workforce Shortages
Jonathan Watanabe, PharmD, MS, PhD, BCGP, discussed gaps within primary care in the context of the American Society of Health-System Pharmacists 2025 Pharmacy Forecast.
Your 2025 Pharmacy Legislation Update
Explore key legislative actions changing pharmacy practice in 2025 and beyond.
Buprenorphine Option Did Not Improve Pain, Reduce Opioid Dosage
Patients prescribed high-dose opioids were given the option to switch to buprenorphine in hopes of improving pain and reducing opioid dosage.